April 2022

INMUNOTEK featured in CIO Bulletin's "50 Most Admired Companies to Watch 2022" list after being nominated for its business performance based on innovative and competitive products in the allergy and immunology fields.
More info

December 2021

INMUNOTEK obtains the CIEGE Seal for excellence in business management for the third consecutive year granted by Informa-ElEconomista. This Seal certifies excellent management over 57 indicators from 10 categories: solvency, profitability, growth, employment, internationalization, corporate social responsibility, customer satisfaction, innovation, commercial risk management and digitization.
More info

November 2021

INMUNOTEK has once again been awarded the CEPYME500 seal in its 2021 edition, which recognizes the 500 leading Spanish companies in business growth, both for their results and their ability to generate added value, employment, innovation and international projection. This is the third year that INMUNOTEK has received this distinguished seal.
More info

July 2021

INMUNOTEK and IDIPAZ (Research Institute of the Hospital Universitario La Paz) have signed an agreement to deepen the mechanisms of action of a new anticancer vaccine developed by INMUNOTEK within the RETOS-Collaboration program with the participation of the Hospital Clínico San Carlos, Universidad Complutense de Madrid and CIB-CSIC.
More info

July 2021

INMUNOTEK has been present at the annual EAACI congress (European Academy of Allergy and Clinical Immunology) held on July 10-12, for the first time in hybrid form between Krakow and Madrid.
More info